电话:025-68136891, 17366374446  

登录  |  注册
中文  English
当前位置:首页 » 教育培训 » 导师介绍 » 高文涛
教育培训
高文涛

高文涛,副主任医师,副教授,硕士生导师。目前担任南京医科大学胰腺研究所副所长,中华医学会江苏分会胰腺学组委员兼秘书,中国抗癌协会胰腺癌专业委员会-微创诊治学组(Minimally Invasive Treatment forPancreatic Cancer(MITPC))委员,国际外科学会(ICS)理事(Fellow)。为江苏省医学重点人才,江苏省 “十三五”重点人才,“江苏省卫生拔尖人才”。

20063月至20074月获 “笹川奖学金”,赴日本爱知癌中心研究所-分子肿瘤学部进行肿瘤表观遗传学研究,201212月至20134月受“江苏省政府留学基金”资助赴Mayo Clinic游学访问。

作为主要参与者获2011年教育部科学技术进步奖(“胰腺癌的基础和临床研究”,排名第四);“胰腺癌发生、发展机制及临床技术创新研究”于 2015年获中华医学科技奖二等奖(排名第四);“胰腺癌关键诊疗技术的创新和应用”2015年获江苏省政府科技进步奖一等奖(排名第四);“胰腺癌基础及临床新技术应用研究”2015年获江苏省医学科技奖一等奖(排名第四)。

所获人才项目及科研课题

201601-201912VASH2PRMT5/KIF11蛋白互作调控组蛋白修饰促进胰腺癌进展的研究,国家自然科学基金面上项目,负责人;

2014.01-2017.01ChIP-Seq分析胰腺癌中VASH2基因促癌作用的下游信号通路,国家自然科学基金面上项目,负责人;

2012.01-2015.12,探索VASH2转录激活对肝细胞癌血管生成和上皮间质转化的作用及机制,国家自然科学基金面上项目,负责人;

2006.1-2008,12,胰腺癌MUC4抗原多表位嵌合DNA疫苗的设计和免疫研究,国家自然科学基金面上项目,负责人;

2012.01-2015.12,胰腺癌中表观遗传机制促进血管生成和EMT的研究,江苏省卫生厅重点项目,负责人;

2009.1-2010.12MCA-Microarray技术研究胰腺癌异常DNA甲基化谱,南京市科技发展计划,负责人;

2004.01-2005.12,筛选/修饰MUC抗原肽改善胰腺癌肿瘤免疫,南京医科大学科技发展基金,负责人;

研究方向

1)表观遗传学是研究基因的核苷酸序列不发生改变的情况下,基因表达的可遗传的变化的一门学科。是目前肿瘤研究最活跃和前沿的邻域之一。本研究团队通过甲基化芯片等筛选方法,国内外首次发现VASH2基因和微小RNA-615,在胰腺癌和肝癌中存在表观遗传学改变,分别发挥促进肿瘤和抑制肿瘤的重要作用,研究结果分别在2013年和2014年权威期刊《Oncogene》报道;目前研究中,利用基因敲除Knock out小鼠和细胞,用Chromatin-IPCO-IP的技术方法,力图阐明其直接作用机制。本研究先后获得3项国家自然科学基金资助,发表SCI论文8篇。

2)胰腺微创手术:由于胰腺手术复杂难度高,是微创手术尚未征服的领域之一。本人在美国Mayo Clinic学习胰腺微创手术,在国内开展推动胰腺外科的微创和腹腔镜手术。

 

主要学术论著

1.   WuJ, Guo F, Wei J, et al. [Surgical treatment for pancreatic neuroendocrineneoplasmas]. Zhejiang da xue xue bao Yi xue ban = Journal of Zhejiang UniversityMedical sciences 2016; 45(1): 31-5.

2.   WeiJ, Liu X, Wu J, et al. Diagnosis and surgical management of insulinomas in 33consecutive patients at a single institution. Langenbeck's archives of surgery2016; 401(7): 1019-25.

3.   TuM, Lu C, Lv N, et al. Vasohibin 2 promotes human luminal breast cancerangiogenesis in a non-paracrine manner via transcriptional activation offibroblast growth factor 2. Cancer letters 2016; 383(2): 272-81.

4.   LuZ, Yin J, Wei J, et al. Small amounts of tissue preserve pancreatic function:Long-term follow-up study of middle-segment preserving pancreatectomy. Medicine2016; 95(46): e5274.

5.   HuoX, Wei J, Liu X, et al. Brunner's gland cyst in combination withgastrointestinal stromal tumor: A case report. Oncology letters 2016; 11(5):3409-12.

6.   GaoW, Dai X, Dai C, et al. Comparison of patency rates and clinical impact ofdifferent reconstruction methods following portal/superior mesenteric veinresection during pancreatectomy. Pancreatology : official journal of theInternational Association of Pancreatology (IAP)  [et al] 2016; 16(6): 1113-23.

7.   WeiJ, Liu X, Wu J, et al. Modified One-layer Duct-to-mucosa PancreaticojejunostomyReduces Pancreatic Fistula After Pancreaticoduodenectomy. International surgery2015.

8.   GeQ, Zhou J, Tu M, et al. Nuclear vasohibin-2 promotes cell proliferation byinducing G0/G1 to S phase progression. Oncology reports 2015; 34(3): 1327-36.

9.   XueX, Zhang Y, Zhi Q, et al. MiR200-upregulated Vasohibin 2 promotes the malignanttransformation of tumors by inducing epithelial-mesenchymal transition inhepatocellular carcinoma. Cell communication and signaling : CCS 2014; 12: 62.

10. TuM, Liu X, Han B, et al. Vasohibin2 promotes proliferation in human breastcancer cells via upregulation of fibroblast growth factor2 andgrowth/differentiation factor15 expression. Molecular medicine reports 2014;10(2): 663-9.

11. MiaoY, Lin S, Gao W. [Surgical strategy for hemorrhagepost-pancreaticoduodenectomy]. Zhonghua wai ke za zhi [Chinese journal ofsurgery] 2014; 52(9): 647-50.

12. LiZ, Tu M, Han B, et al. Vasohibin 2 decreases the cisplatin sensitivity ofhepatocarcinoma cell line by downregulating p53. PloS one 2014; 9(3): e90358.

13. SunJ, Tu M, Han B, et al. Generation and characterization of rabbit polyclonalantibodies against Vasohibin-2 for determination of its intracellularlocalization. International journal of oncology 2013; 43(1): 255-61.

14. ChenJ, Li Q, An Y, et al. CEACAM6 induces epithelial-mesenchymal transition andmediates invasion and metastasis in pancreatic cancer. International journal ofoncology 2013; 43(3): 877-85.

15. AnY, Cai B, Chen J, et al. MAP3K10 promotes the proliferation and decreases thesensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 andGli-2. Cancer letters 2013; 329(2): 228-35.

16. ChenM, Xue X, Wang F, et al. Expression and promoter methylation analysis ofATP-binding cassette genes in pancreatic cancer. Oncology reports 2012; 27(1):265-9.

17. XueX, Lu Z, Tang D, et al. Galectin-1 secreted by activated stellate cells inpancreatic ductal adenocarcinoma stroma promotes proliferation and invasion ofpancreatic cancer cells: an in vitro study on the microenvironment ofpancreatic ductal adenocarcinoma. Pancreas 2011; 40(6): 832-9.

18. ZhuZ, Gao W, Qian Z, Miao Y. Genetic variation of miRNA sequence in pancreaticcancer. Acta biochimica et biophysica Sinica 2009; 41(5): 407-13.

19. WuJ, Wei J, Meng K, et al. Identification of an HLA-A*0201-restrictive CTLepitope from MUC4 for applicable vaccine therapy. Immunopharmacology andimmunotoxicology 2009; 31(3): 468-76.

20. WeiJ, Gao W, Wu J, et al. Dendritic cells expressing a combined PADRE/MUC4-derivedpolyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Cancerbiotherapy & radiopharmaceuticals 2008; 23(1): 121-8.

21. GaoW, Kondo Y, Shen L, et al. Variable DNA methylation patterns associated withprogression of disease in hepatocellular carcinomas. Carcinogenesis 2008;29(10): 1901-10.